Rezolute RZLT
NASDAQ RZLT
$4.07 +0.05 (+1.24%)
At close: Nov 11, 2026 · 4:00 PM EST

Rezolute (RZLT) EBITDA Margin (2019 - 2020)

Updated

Rezolute (RZLT) reported EBITDA Margin of -120666.67% for fiscal Q1 2021 (quarter ended Sep 30, 2020), down 49706.67 percentage points from the prior quarter.

Analysis

Rezolute (RZLT) EBITDA Margin (2019 - 2020) Analysis & Trends

Over the twelve months ended Sep 30, 2020, Rezolute's EBITDA Margin came in at -20596.74%; for FY2020 (ended Jun 30, 2020), it came in at -10905.85%, up 28179.39 percentage points from FY2019.

  • By fiscal year, EBITDA Margin came in at -39085.25% in FY2019.
  • The fiscal Q1 2021 figure ranks as the lowest quarterly EBITDA Margin since fiscal Q3 2019.
  • Per Business Quant data, the three fiscal quarters before Q1 2021 came in at -70960.00% (Q4 2020), -16883.33% (Q3 2020) and -12437.04% (Q2 2020).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 36.69%
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 32.68%
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 46.88%
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 40.60%
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn 39.77%
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 46.62%
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 50.63%
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 42.49%
10 Rezolute 388.82 Mn -62.24 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2020 -120,666.67%
Jun 30, 2020 -70,960.00%
Mar 31, 2020 -16,883.33%
Dec 31, 2019 -12,437.04%
Jun 30, 2019 -6,489.80%
Mar 31, 2019 -145,904.08%
API Access

Rezolute EBITDA Margin API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=ebitda-margin&ticker=RZLT&period=max&api_key=YOUR_API_KEY